Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Descartes-08 in Generalized Myasthenia Gravis
NCT04146051Phase 2Active, not recruiting
- Sponsor
- Cartesian Therapeutics
- Start
- Dec 2019
- Primary completion
- Jan 2026
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 2
01
Overview
Phase 2, randomised trial of Descartes-08 in myasthenia gravis (MG) (3 arms), sponsored by Cartesian Therapeutics. Primary endpoint: Proportion of patients with MG Composite improvement of ≥5 points at Day 85. Started Dec 2019; status: active, not recruiting.
02
Drugs
Descartes-08
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT04146051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04146051.